Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 1/20 | 0.70 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.68 |
| ▸ | JAK3 | P52333 | 5/20 | 0.67 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.61 |
| ▸ | BTK | Q06187 | 6/20 | 0.57 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | JAK1 | P23458 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | AKT2 | P31751 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | TEC | P42680 | 1/20 | 0.55 |
| ▸ | TXK | P42681 | 1/20 | 0.55 |
| ▸ | BMX | P51813 | 1/20 | 0.55 |
| ▸ | ITK | Q08881 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7851332 | 0.92 | PBK (0.60) | PBKDOT1LJAK3LRRK2BTK | |
| SCHEMBL3953793 | 0.91 | DOT1L (0.68) | PBKDOT1LJAK3BTKJAK2 | |
| SCHEMBL2018105 | 0.89 | JAK3 (0.69) | PBKDOT1LJAK3BTKJAK2 | |
| SCHEMBL30056647 | 0.85 | AKT2 (0.69) | DOT1LJAK3JAK2JAK1KIT | |
| SCHEMBL22645626 | 0.85 | AKT2 (0.69) | DOT1LJAK3JAK2JAK1KIT | |
| SCHEMBL3955700 | 0.84 | JAK3 (0.61) | DOT1LJAK3BTKJAK2JAK1 | |
| SCHEMBL3953560 | 0.84 | JAK3 (0.61) | DOT1LJAK3BTKJAK2JAK1 | |
| Diethylamine SCHEMBL27437004 | 0.84 | JAK3 (0.61) | DOT1LJAK3BTKJAK2JAK1 | |
| SCHEMBL28380201 | 0.83 | JAK3 (0.65) | DOT1LJAK3BTKJAK2JAK1 | |
| Nipecotic Acid SCHEMBL7851570 | 0.83 | DOT1L (0.58) | PBKDOT1LJAK3BTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| CN-1125070-C | Pyrrolo [2,3-d] pyrmidine compounds | PFIZER PROD INC (US) | 2003-10-22 | — | — | CN | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
| CN-1305479-A | Pyrrolo [2,3-d] pyrmidine compounds | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | PBK 229/4885DOT1L 1902/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.